80 related articles for article (PubMed ID: 33278174)
1. Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients.
Lapidot M; Gill RR; Mazzola E; Freyaldenhoven S; Swanson SJ; Jaklitsch MT; Sugarbaker DJ; Bueno R
Ann Surg; 2022 Jun; 275(6):1212-1220. PubMed ID: 33278174
[TBL] [Abstract][Full Text] [Related]
2. Prolonged survival and novel prognostic factors in women with pleural mesothelioma treated with extended pleurectomy decortication.
Lapidot M; Mazzola E; Bueno R
Transl Lung Cancer Res; 2024 Apr; 13(4):811-820. PubMed ID: 38736489
[TBL] [Abstract][Full Text] [Related]
3. Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma.
Nakamura A; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Matsumoto S; Kondo N; Kijima T; Hasegawa S
J Thorac Dis; 2020 Nov; 12(11):6712-6721. PubMed ID: 33282372
[TBL] [Abstract][Full Text] [Related]
4. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma.
Karnan S; Ota A; Murakami H; Rahman ML; Hasan MN; Wahiduzzaman M; Hanamura I; Quang Vu L; Inoko A; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cell Death Discov; 2020 Nov; 6(1):127. PubMed ID: 33298865
[TBL] [Abstract][Full Text] [Related]
5. The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis.
Lauk O; Bruestle K; Neuer T; Battilana B; Nguyen TDL; Frauenfelder T; Stahel R; Weder W; Curioni-Fontecedro A; Opitz I
Front Oncol; 2020; 10():588563. PubMed ID: 33304848
[TBL] [Abstract][Full Text] [Related]
6. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S; O'Brien M; Evangelista M; Harris TJ; Steinohrt NS; Jenkins LJ; Walkiewicz M; O'Donoghue RJJ; Poh AR; Thapa B; Williams DS; Leong T; Mariadason JM; Li X; Cebon J; Lee EF; John T; Fairlie WD
Cell Death Discov; 2020 Oct; 6(1):114. PubMed ID: 33298868
[TBL] [Abstract][Full Text] [Related]
7. Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma.
Wright C; Verma V; Barsky AR; Haque W; Polamraju PV; Ludmir EB; Zaorsky NG; Lehrer EJ; Trifiletti DM; Grover S; Friedberg JS; Simone CB
J Thorac Dis; 2020 Nov; 12(11):6476-6493. PubMed ID: 33282350
[TBL] [Abstract][Full Text] [Related]
8. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
Cho BCJ; Donahoe L; Bradbury PA; Leighl N; Keshavjee S; Hope A; Pal P; Cabanero M; Czarnecka K; McRae K; Tsao MS; de Perrot M
Lancet Oncol; 2021 Feb; 22(2):190-197. PubMed ID: 33450184
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders.
Park EK; Johnson AR; Wilson D; Thomas PS; Yates DH
Saf Health Work; 2020 Dec; 11(4):425-430. PubMed ID: 33329908
[TBL] [Abstract][Full Text] [Related]
11. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
12. Heterozygous germline
Bononi A; Goto K; Ak G; Yoshikawa Y; Emi M; Pastorino S; Carparelli L; Ferro A; Nasu M; Kim JH; Suarez JS; Xu R; Tanji M; Takinishi Y; Minaai M; Novelli F; Pagano I; Gaudino G; Pass HI; Groden J; Grzymski JJ; Metintas M; Akarsu M; Morrow B; Hassan R; Yang H; Carbone M
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33466-33473. PubMed ID: 33318203
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence
Cheng YY; Yuen ML; Rath EM; Johnson B; Zhuang L; Yu TK; Aleksova V; Linton A; Kao S; Clarke CJ; McCaughan BC; Takahashi K; Lee K
Front Oncol; 2020; 10():579327. PubMed ID: 33304846
[TBL] [Abstract][Full Text] [Related]
14. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I; Martin SA; Barbarino M; Melani A; Silvestri R; Bottaro M; Paolicchi E; Corrado A; Cipollini M; Melaiu O; Giordano A; Luzzi L; Gemignani F; Landi S
Invest New Drugs; 2021 Jun; 39(3):644-657. PubMed ID: 33300108
[TBL] [Abstract][Full Text] [Related]
15. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
Collins DC; Sundar R; Constantinidou A; Dolling D; Yap TA; Popat S; O'Brien ME; Banerji U; de Bono JS; Lopez JS; Tunariu N; Minchom A
BMC Cancer; 2020 Dec; 20(1):1210. PubMed ID: 33298007
[TBL] [Abstract][Full Text] [Related]
16. Diagnostics in Pleural Disease.
Sundaralingam A; Bedawi EO; Rahman NM
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33291748
[TBL] [Abstract][Full Text] [Related]
17. Malignant Pleural Mesothelioma: Time Is Running Out.
Lococo F
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33567623
[TBL] [Abstract][Full Text] [Related]
18. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Nadal E; Bosch-Barrera J; Cedrés S; Coves J; García-Campelo R; Guirado M; López-Castro R; Ortega AL; Vicente D; de Castro-Carpeño J
Clin Transl Oncol; 2021 May; 23(5):980-987. PubMed ID: 33538989
[TBL] [Abstract][Full Text] [Related]
19. Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting.
Ringgaard Petersen T; Panou V; Meristoudis C; Weinreich UM; Røe OD
Acta Oncol; 2021 Apr; 60(4):521-527. PubMed ID: 33502280
[TBL] [Abstract][Full Text] [Related]
20. Update on biology and management of mesothelioma.
Asciak R; George V; Rahman NM
Eur Respir Rev; 2021 Mar; 30(159):. PubMed ID: 33472960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
